Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI.
Inova Heart and Vascular Institute, Falls Church, VA.
Am Heart J. 2020 Sep;227:1-8. doi: 10.1016/j.ahj.2020.05.014. Epub 2020 May 30.
Risk scores including the Thrombolysis in Myocardial Infarction (TIMI) score; History, Electrocardiogram, Age, Risk Factors, and Troponin (HEART) score; and Simplified Emergency Department Assessment of Chest Pain Score (sEDACS) have been used to evaluate patients with symptoms suggestive of acute myocardial infarct (AMI). This study assessed prognostic utility of cardiac risk stratification scores when augmented with a high-sensitivity cardiac troponin-I assay (hs-cTnI).
This study enrolled 2,505 suspected AMI patients at 29 hospitals in the United States from April 2015 to April 2016. Blood samples were tested for hs-cTnI on the Atellica IM TnIH Assay (Siemens Healthineers). Patients were considered low risk for death/AMI with a TIMI score = 0, HEART ≤3, sEDACS ≤15, and hs-cTnI <45 ng/L (99th percentile) at time 0 and 2-3 hours.
There were 2,336 patients included after exclusions for ST-segment elevation myocardial infarction or incomplete data. At 30 days, 283 patients (12.1%) had been diagnosed with AMI, and there were 24 (1.0%) deaths and 213 (9.1%) revascularizations. Of 298 patients with death or AMI, 258 (86.6%) had elevated hs-cTnI. The HEART score and sEDACS identified 34.5% and 36.6% of patients as low risk, respectively. This was significantly more than the 12.1% identified by the TIMI score (P < .01).
The TIMI, HEART, and sEDACS scores all identify low-risk patients when combined with hs-cTnI measurements. The HEART score and sEDACS identified more low-risk patients compared to the TIMI score. These patients could be considered for discharge from the emergency department without further testing.
本研究旨在评估高敏心肌肌钙蛋白 I 检测(hs-cTnI)联合心脏风险分层评分对疑似急性心肌梗死(AMI)患者的预后评估作用。
本研究共纳入 2015 年 4 月至 2016 年 4 月美国 29 家医院的 2505 例疑似 AMI 患者。采用西门子医疗 Atellica IM TnIH 检测试剂盒(Atellica IM TnIH Assay)检测 hs-cTnI。如果 TIMI 评分为 0 分、HEART 评分≤3 分、sEDACS 评分≤15 分且 hs-cTnI 在 0 小时和 2-3 小时时<45ng/L(99 百分位),则认为患者死亡/发生 AMI 的风险较低。
排除 ST 段抬高型心肌梗死或数据不完整的患者后,共纳入 2336 例患者。在 30 天内,有 283 例(12.1%)患者被诊断为 AMI,有 24 例(1.0%)死亡和 213 例(9.1%)血运重建。在 298 例发生死亡或 AMI 的患者中,258 例(86.6%)hs-cTnI 升高。HEART 评分和 sEDACS 分别识别出 34.5%和 36.6%的低风险患者,明显高于 TIMI 评分的 12.1%(P<0.01)。
TIMI、HEART 和 sEDACS 评分结合 hs-cTnI 测量均可识别低风险患者。与 TIMI 评分相比,HEART 评分和 sEDACS 评分识别出了更多的低风险患者。这些患者可考虑从急诊室出院,无需进一步检查。